In November 2000 NICE issued a Technology Appraisal Guidance regarding zanamivir
which recommended the use of the drug, in those “at risk” adults who present
within 36 hours of the onset of influenza like illness (ILI) and who are able to
commence treatment within 48 hours of the onset of symptoms. The guidance was to
become active when influenza is known to be circulating in the community, as
indicated by community based virological and general practice activity
surveillance schemes (this will be confirmed by the DoH).
“At risk”
individuals are defined as
- Age 65 years or over
- Chronic respiratory disease, including chronic obstructive pulmonary
disease (COPD) and asthma, requiring regular medication
- Significant cardiovascular disease (excluding individuals with
hypertension)
- Immunocompromised, including that due to illness or treatment including
asplenia or splenic dysfunction
- Diabetes mellitus
Influenza